{"success":true,"data":{"pressRelease":{"id":"145364","rtpr_id":"nBwJS2tpa-20260916","ticker":"DNA","exchange":"NYSE","all_tickers":["DNA"],"title":"Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data","author":"Business Wire","published_at":"2026-09-16T13:52:00.085Z","article_body":"Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between\nAI Models and Lab Data\n\nIntegration puts Ginkgo’s biological data generation services at the heart\nof the industry’s most prominent AI-driven drug discovery network\n\nGinkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdatapoints.ginkgo.bio%2F&esheet=54605297&newsitemid=20260916894592&lan=en-US&anchor=Ginkgo+Datapoints&index=1&md5=f6409a7be8a85eb00e4b5f5f45e8adcf)\noffering has entered into a new agreement with Lilly TuneLab\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftunelab.lilly.com%2F&esheet=54605297&newsitemid=20260916894592&lan=en-US&anchor=Lilly+TuneLab&index=2&md5=9c74310b473fa66d473ef9d0a5442680)\n, a collaborative AI/ML drug discovery platform created by Eli Lilly and\nCompany (Lilly). TuneLab supports biotech innovation by enabling participating\ncompanies to access AI/ML drug discovery models trained on decades of Lilly's\nproprietary research data.\n\nGinkgo Datapoints will provide discovery data generation services, including\nsmall molecule developability (ADME) and antibody developability testing, to\nTuneLab companies.\n\n\"The combination of Ginkgo’s automation and TuneLab’s collaboration\nplatform aims to accelerate next-generation therapeutic development across the\nindustry. TuneLab is attracting many biotechs who benefit from access to\npowerful predictive models that are constantly improving via contributions\nfrom the network. Layering on Ginkgo's ability to quickly generate\nhigh-quality, AI-ready datasets at any scale, we believe TuneLab participants\nwill be able to close the loop between digital design and biological reality\nfaster than ever before,\" said John Androsavich, PhD, General Manager at\nGinkgo Datapoints.\n\nFor TuneLab's biotech partners, this means access to state-of-the-art lab\nautomation capable of running experiments without manual bottlenecks. Ginkgo's\nantibody and small molecule developability screening can turn around results\nin ML-ready formats that plug directly into TuneLab's predictive models —\nclosing the loop between a biotech's AI-generated hypothesis and validated lab\ndata in days rather than months.\n\nGinkgo’s delivery of standardized assay protocols across the TuneLab\necosystem is expected to enable AI/ML models to learn more efficiently,\nincreasing the overall impact of the TuneLab platform. New TuneLab members can\nnow submit Datapoints’ generated data to access additional platform model\nbenefits.\n\nThe agreement marks the latest expansion of Ginkgo Datapoints' collaborative\nwork in offering differentiated services tailored to AI/ML. By partnering and\nworking with top companies, Ginkgo is connecting biopharma partners'\npredictive models to real-world experimental data at scale.\n\nLilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly\nGateway Labs, and Lilly ExploR&D, which together support biotech\ninnovation by providing access to strategic capital, lab space and technology,\nand research and development capabilities.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo’s in-house autonomous lab is also available as a\n“Cloud Lab” through our Datapoints and Solutions contract research\nservices. For more information, visit ginkgobioworks.com, read our blog, or\nfollow us on social media channels such as X (@Ginkgo), Instagram\n(@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis press release contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding the\ncapabilities and potential success of Ginkgo's autonomous labs. These\nforward-looking statements generally are identified by the words \"believe,\"\n\"can,\" \"project,\" \"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\"\n\"strategy,\" \"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\"\n\"will be,\" \"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to realize near-term and long-term cost savings associated with our\nsite consolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith and (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown. The foregoing\nlist of factors is not exhaustive. You should carefully consider the foregoing\nfactors and the other risks and uncertainties described in the \"Risk Factors\"\nsection of Ginkgo's annual report on Form 10-K filed with the U.S. Securities\nand Exchange Commission (the \"SEC\") on February 26, 2026, and other documents\nfiled by Ginkgo from time to time with the SEC. These filings identify and\naddress other important risks and uncertainties that could cause actual events\nand results to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916894592/en/\n(https://www.businesswire.com/news/home/20260916894592/en/)\n\nGINKGO BIOWORKS INVESTOR CONTACT: investors@ginkgobioworks.com\n(mailto:investors@ginkgobioworks.com)\n\nGINKGO BIOWORKS MEDIA CONTACT: press@ginkgobioworks.com\n(mailto:press@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwJS2tpa-20260916","title":"Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data","author":"Business Wire","ticker":"DNA","created":"2026-09-16T13:52:00.085Z","tickers":["DNA"],"exchange":"NYSE","article_body":"Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between\nAI Models and Lab Data\n\nIntegration puts Ginkgo’s biological data generation services at the heart\nof the industry’s most prominent AI-driven drug discovery network\n\nGinkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdatapoints.ginkgo.bio%2F&esheet=54605297&newsitemid=20260916894592&lan=en-US&anchor=Ginkgo+Datapoints&index=1&md5=f6409a7be8a85eb00e4b5f5f45e8adcf)\noffering has entered into a new agreement with Lilly TuneLab\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftunelab.lilly.com%2F&esheet=54605297&newsitemid=20260916894592&lan=en-US&anchor=Lilly+TuneLab&index=2&md5=9c74310b473fa66d473ef9d0a5442680)\n, a collaborative AI/ML drug discovery platform created by Eli Lilly and\nCompany (Lilly). TuneLab supports biotech innovation by enabling participating\ncompanies to access AI/ML drug discovery models trained on decades of Lilly's\nproprietary research data.\n\nGinkgo Datapoints will provide discovery data generation services, including\nsmall molecule developability (ADME) and antibody developability testing, to\nTuneLab companies.\n\n\"The combination of Ginkgo’s automation and TuneLab’s collaboration\nplatform aims to accelerate next-generation therapeutic development across the\nindustry. TuneLab is attracting many biotechs who benefit from access to\npowerful predictive models that are constantly improving via contributions\nfrom the network. Layering on Ginkgo's ability to quickly generate\nhigh-quality, AI-ready datasets at any scale, we believe TuneLab participants\nwill be able to close the loop between digital design and biological reality\nfaster than ever before,\" said John Androsavich, PhD, General Manager at\nGinkgo Datapoints.\n\nFor TuneLab's biotech partners, this means access to state-of-the-art lab\nautomation capable of running experiments without manual bottlenecks. Ginkgo's\nantibody and small molecule developability screening can turn around results\nin ML-ready formats that plug directly into TuneLab's predictive models —\nclosing the loop between a biotech's AI-generated hypothesis and validated lab\ndata in days rather than months.\n\nGinkgo’s delivery of standardized assay protocols across the TuneLab\necosystem is expected to enable AI/ML models to learn more efficiently,\nincreasing the overall impact of the TuneLab platform. New TuneLab members can\nnow submit Datapoints’ generated data to access additional platform model\nbenefits.\n\nThe agreement marks the latest expansion of Ginkgo Datapoints' collaborative\nwork in offering differentiated services tailored to AI/ML. By partnering and\nworking with top companies, Ginkgo is connecting biopharma partners'\npredictive models to real-world experimental data at scale.\n\nLilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly\nGateway Labs, and Lilly ExploR&D, which together support biotech\ninnovation by providing access to strategic capital, lab space and technology,\nand research and development capabilities.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo’s in-house autonomous lab is also available as a\n“Cloud Lab” through our Datapoints and Solutions contract research\nservices. For more information, visit ginkgobioworks.com, read our blog, or\nfollow us on social media channels such as X (@Ginkgo), Instagram\n(@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis press release contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding the\ncapabilities and potential success of Ginkgo's autonomous labs. These\nforward-looking statements generally are identified by the words \"believe,\"\n\"can,\" \"project,\" \"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\"\n\"strategy,\" \"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\"\n\"will be,\" \"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to realize near-term and long-term cost savings associated with our\nsite consolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith and (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown. The foregoing\nlist of factors is not exhaustive. You should carefully consider the foregoing\nfactors and the other risks and uncertainties described in the \"Risk Factors\"\nsection of Ginkgo's annual report on Form 10-K filed with the U.S. Securities\nand Exchange Commission (the \"SEC\") on February 26, 2026, and other documents\nfiled by Ginkgo from time to time with the SEC. These filings identify and\naddress other important risks and uncertainties that could cause actual events\nand results to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916894592/en/\n(https://www.businesswire.com/news/home/20260916894592/en/)\n\nGINKGO BIOWORKS INVESTOR CONTACT: investors@ginkgobioworks.com\n(mailto:investors@ginkgobioworks.com)\n\nGINKGO BIOWORKS MEDIA CONTACT: press@ginkgobioworks.com\n(mailto:press@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-16T13:52:00.122114755Z","server_sent_at_ms":1789566720122},"received_at":"2026-09-16T13:52:00.179Z","source_url":"https://www.businesswire.com/news/home/20260916894592/en/"},"analysis":{"id":"134196","press_release_id":"145364","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":["No financial terms, deal value, or revenue contribution disclosed for the partnership"],"eventType":"partnership","narrative":"Ginkgo Bioworks' Datapoints unit signed an agreement with Lilly TuneLab, the collaborative AI/ML drug discovery platform created by Eli Lilly, to provide discovery data generation services to TuneLab member companies.\n\nGinkgo will supply small molecule developability (ADME) and antibody developability testing in ML-ready formats that plug directly into TuneLab's predictive models, with turnaround expected in days rather than months.\n\nThe deal embeds Ginkgo's lab automation inside Lilly's biotech partner network and allows new TuneLab members to submit Datapoints-generated data for additional platform model benefits; no financial terms or revenue contribution were disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strategic validation as Ginkgo's lab-data services plug into Lilly's TuneLab AI network, but unquantified until contract economics surface."},"keyFigures":{},"quotedText":"The combination of Ginkgo’s automation and TuneLab’s collaboration\nplatform aims to accelerate next-generation therapeutic development across the\nindustry.","namedEntities":{"people":[{"name":"John Androsavich, PhD","role":"General Manager, Ginkgo Datapoints"}],"products":["Ginkgo Datapoints","Lilly TuneLab","Lilly Catalyze360","Lilly Ventures","Lilly Gateway Labs","Lilly ExploR&D"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer"},{"name":"Eli Lilly and Company","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A business-development win that embeds Ginkgo's data generation services inside Eli Lilly's TuneLab AI drug discovery network, but the release discloses no financial terms, contract value, or revenue contribution. Strategically positive, financially unquantified."},"tickerRelevance":{"others":[{"ticker":"LLY","relevance":"partner"}],"primary":"DNA"},"globalImportance":28,"audienceRelevance":38,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","partnerTier":"mega-cap-pharma","eventGravity":"partnership-without-financial-terms","retailFavoriteBoost":"DNA has a retail following; Lilly brand adds name recognition","financialTermsDisclosed":false}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Ginkgo Bioworks' Datapoints unit signed an agreement with Lilly TuneLab, the collaborative AI/ML drug discovery platform created by Eli Lilly, to provide discovery data generation services to TuneLab member companies.\n\nGinkgo will supply small molecule developability (ADME) and antibody developability testing in ML-ready formats that plug directly into TuneLab's predictive models, with turnaround expected in days rather than months.\n\nThe deal embeds Ginkgo's lab automation inside Lilly's biotech partner network and allows new TuneLab members to submit Datapoints-generated data for additional platform model benefits; no financial terms or revenue contribution were disclosed.","key_figures":{},"named_entities":{"people":[{"name":"John Androsavich, PhD","role":"General Manager, Ginkgo Datapoints"}],"products":["Ginkgo Datapoints","Lilly TuneLab","Lilly Catalyze360","Lilly Ventures","Lilly Gateway Labs","Lilly ExploR&D"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer"},{"name":"Eli Lilly and Company","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T13:52:46.424Z","global_importance":28,"audience_relevance":38,"importance_components":{"tickerTier":"mid-cap","partnerTier":"mega-cap-pharma","eventGravity":"partnership-without-financial-terms","retailFavoriteBoost":"DNA has a retail following; Lilly brand adds name recognition","financialTermsDisclosed":false}},"durationMs":46240,"modelName":"glm-5.3-flash"}}